A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy

被引:11
|
作者
Adhikarla, Vikram [1 ]
Awuah, Dennis [2 ]
Brummer, Alexander B. [1 ]
Caserta, Enrico [3 ]
Krishnan, Amrita [2 ]
Pichiorri, Flavia [3 ]
Minnix, Megan [4 ]
Shively, John E. [4 ]
Wong, Jeffrey Y. C. [5 ]
Wang, Xiuli [2 ]
Rockne, Russell C. [1 ]
机构
[1] City Hope Natl Med Ctr, Div Math Oncol, Dept Computat & Quantitat Med, Beckman Res Inst,Natl Med Ctr, Duarte, CA 91010 USA
[2] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Beckman Res Inst, Natl Med Ctr, Duarte, CA 91010 USA
[3] City Hope Natl Med Ctr, Dept Hematol Malignancies Translat Sci, Beckman Res Inst, Natl Med Ctr, Duarte, CA 91010 USA
[4] City Hope Natl Med Ctr, Dept Mol Imaging & Therapy, Natl Med Ctr, Duarte, CA 91010 USA
[5] City Hope Natl Med Ctr, Dept Radiat Oncol, Natl Med Ctr, Duarte, CA 91010 USA
基金
美国国家卫生研究院;
关键词
CAR-T; targeted radionuclide therapy; TRT; mathematical model; multiple myeloma; immunotherapy; daratumumab; CS1; combination therapy; alpha particle therapy; actinium-225; IMMUNOTHERAPY;
D O I
10.3390/cancers13205171
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Targeted radionuclide therapy (TRT) has recently seen a surge in popularity with the use of radionuclides conjugated to small molecules and antibodies. Similarly, immunotherapy also has shown promising results, an example being chimeric antigen receptor T cell (CAR-T) therapy in hematologic malignancies. Moreover, TRT and CAR-T therapies possess unique features that require special consideration when determining how to dose as well as the timing and sequence of combination treatments including the distribution of the TRT dose in the body, the decay rate of the radionuclide, and the proliferation and persistence of the CAR-T cells. These characteristics complicate the additive or synergistic effects of combination therapies and warrant a mathematical treatment that includes these dynamics in relation to the proliferation and clearance rates of the target tumor cells. Here, we combine two previously published mathematical models to explore the effects of dose, timing, and sequencing of TRT and CAR-T cell-based therapies in a multiple myeloma setting. We find that, for a fixed TRT and CAR-T cell dose, the tumor proliferation rate is the most important parameter in determining the best timing of TRT and CAR-T therapies.
引用
收藏
页数:14
相关论文
共 50 条
  • [11] Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies
    Xiao, Xinyi
    Wang, Yazhuo
    Zou, Zhengbang
    Yang, Yufei
    Wang, Xinyu
    Xin, Xin
    Tu, Sanfang
    Li, Yuhua
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [12] CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY FOR ASPERGILLOSIS
    Kumar, P.
    Wurster, S.
    daSilva, T.
    Hauser, P.
    Neelapu, S. S.
    Kontoyiannis, D.
    CYTOTHERAPY, 2024, 26 (06) : S10 - S11
  • [13] Chimeric antigen receptor T-cell therapy for melanoma
    Razavi, Azadehsadat
    Keshavarz-Fathi, Mahsa
    Pawelek, John
    Rezaei, Nima
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2021, 17 (03) : 209 - 223
  • [14] Future directions in chimeric antigen receptor T cell therapy
    Maude, Shannon L.
    CURRENT OPINION IN PEDIATRICS, 2017, 29 (01) : 27 - 33
  • [15] Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma
    Ma, Kun
    Hu, Ping
    CANCERS, 2023, 15 (23)
  • [16] Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges
    Dhakal, Binod
    Hari, Parameswaran N.
    Usmani, Saad Z.
    Hamadani, Mehdi
    BONE MARROW TRANSPLANTATION, 2021, 56 (01) : 9 - 19
  • [17] Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma
    Zhou, Shuchang
    Sun, Han
    Choi, Sun Il
    Yin, Jinlong
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2023, 28 (09):
  • [18] Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future
    Li, Long
    Zhu, Xiqun
    Qian, Yu
    Yuan, Xiangling
    Ding, Yi
    Hu, Desheng
    He, Xin
    Wu, Yuan
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [19] Chimeric antigen receptor T-cell therapy in hematopoietic and nonhematopoietic malignancies
    Ahmad, Faizan
    BIOMEDICAL AND BIOTECHNOLOGY RESEARCH JOURNAL, 2020, 4 (03): : 179 - 185
  • [20] The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma
    Feinberg, Daniel
    Paul, Barry
    Kang, Yubin
    CELLULAR IMMUNOLOGY, 2019, 345